- Prev close
- $150.56
- Day range
- $148.65 – $153.28
Gilead’s +1.4% move sits near its 52-week high of $157.29 and looks more like a normal session than a stock-specific break from fundamentals; the picture is supported by +5.5% revenue growth and a forward PE of 25.3, but operating and net margins remain negative.
GILD
GILEAD SCIENCES INC
As of Sep 22, 2026
66/100
Worth keeping an eye onHealth ScoreMove driver
The main driver looks stock-specific rather than market-wide: GILD rose +1.4% while the S&P 500 was -0.0% and the Nasdaq 100 was +0.8%, so the session was modestly better than the tape rather than explained by it. The move was also relatively contained versus the recent company-news backdrop, which includes Bixlenvo approval and the Assembly Biosciences HSV program update; that points to company-specific optimism, not a broad market rerating.
Volatility check
This looks like ordinary volatility, not a break in the fundamentals. Revenue is still growing at +5.5% YoY on a TTM basis and +10.2% YoY in the latest quarter, while gross margin is 79.6%, so the top line and product economics are intact even though operating margin is -8.2% and net margin is -10.6%. Valuation is not cheap at a forward PE of 25.3 and a PEG of 2.53 — PEG means P/E divided by growth, so investors are paying 2.53 times the growth rate — which means good news can move the shares, but the move itself is still well within what those fundamentals can support. Beta is 0.40, which fits a lower-volatility name.
Earnings setup
The next earnings date is not available this period, so I can’t place a specific report on the calendar. The facts provided also do not include consensus revenue or EPS estimates, so there is no reliable estimate set to quote here. What the market is likely focused on is whether HIV momentum from Bixlenvo is showing up in revenue growth, whether the company can narrow the gap between 79.6% gross margin and the -8.2% operating margin, and how the Assembly Biosciences collaboration and the new research center feed the longer-term pipeline.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track GILD with WhyIHold
Get a plain-English explanation the next time GILEAD SCIENCES INC makes a big move — so you know whether it's benign or worth your attention.